Continues longstanding commitment to developing and advancing standards and organizations critical to web and internet operations AMSTERDAM, Sept. 13, 2024…
CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug…
As previously communicated, Terranet has been selected to participate in MobilityXlab’s prestigious accelerator program, where several leading companies in the…
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous…